Compare HSY & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSY | ONC |
|---|---|---|
| Founded | 1894 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | HSY | ONC |
|---|---|---|
| Price | $202.50 | $348.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $196.69 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 1.9M | 304.0K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.69 | 0.58 |
| Revenue | ★ $11,489,095,000.00 | $4,972,687,000.00 |
| Revenue This Year | $4.37 | $895.40 |
| Revenue Next Year | $3.55 | $22.04 |
| P/E Ratio | ★ $30.11 | $592.40 |
| Revenue Growth | 4.71 | ★ 50.43 |
| 52 Week Low | $140.13 | $196.45 |
| 52 Week High | $204.41 | $385.22 |
| Indicator | HSY | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 68.06 | 58.55 |
| Support Level | $189.48 | $328.91 |
| Resistance Level | $195.70 | $353.00 |
| Average True Range (ATR) | 4.66 | 9.40 |
| MACD | 0.67 | 0.44 |
| Stochastic Oscillator | 89.23 | 74.83 |
Hershey is a leading US confectionery manufacturer (around a $54 billion market, according to Euromonitor), controlling around 36% of the domestic chocolate aisle. Beyond its namesake label, the firm's portfolio has expanded over the last 85 years and now comprises 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the US, including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confectionery business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its portfolio, as well as Pirate Brands and Dot's Pretzels over the past few years.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.